
Novartis has gained EU approval for everolimus to be used to treat a rare non-cancerous tumour. Everolimus is already marketed …
Novartis’ novel cancer drug Votubia has reduced the size of SEGA brain tumours in a late-stage trial. Votubia (or everolimus …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

